|
|
|
| Relationship between the expression level of EB virus gene fragment and the pathogenesis of nasopharyngeal carcinoma |
| LIU Jieqiong CAO Yongqing LI Ke QI Hui |
| Department of Hematology and Oncology, the First Hospital of Changsha, Hu'nan Province, Changsha 410005, China |
|
|
|
Abstract Objective To explore the correlation of BCRF-1 mRNA expression with nasopharyngeal carcinoma and its influence on immune function. Methods A total of 54 patients with nasopharyngeal carcinoma (nasopharyngeal carcinoma group) who were admitted to the First Hospital of Changsha (“our hospital” for short) from January 2017 to May 2018 were enrolled in the study. At the same time, 50 cases of non-neoplastic nasopharyngeal patients treated at the same time in our hospital were selected as the control group. The expression of BCRF-1 mRNA was detected by real-time PCR, the T cell subsets were determined by flow cytometry. Results Compared with control group, the relative expression of BCRF-1 mRNA was significantly increased (P ＜ 0.05). And the relative expression of BCRF-1 mRNA in TNM stage T3-T4 and N2-N3 was significantly higher than that in TNM stage T1-T2 and N0-N1 stage (P ＜ 0.05). The percentage of CD4+ T cells and CD4+/CD8+ in the high expression of BCRF-1 mRNA group was significantly lower than that in the low expression of BCRF-1 mRNA group, while the proportion of CD8+ T cells was significantly higher than that in the low expression of BCRF-1 mRNA group (all P < 0.05). Conclusion The expression of BCRF-1 mRNA are may be related to TNM stage T and N of nasopharyngeal carcinoma, and its high expression can inhibit the immune function of patients.
|
|
|
|
|
|
[1] 容敏华，李秋林，曹骥，等.2013年广西肿瘤登记地区鼻咽癌发病和死亡分析[J].中国癌症防治杂志，2017，9（2）：104-110.
[2] Li J，Chen S，Peng S，et al. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics [J]. Int J Biol Sci，2018，14（5）：549-556.
[3] Li A，Zhang Y，Zhang C，et al. Pathologic study of tumour extension for clinically localized unilateral nasopharyngeal carcinoma：Should the contralateral side be included in the clinical target volume? [J]. J Med Imaging Radiat Oncol，2018，34（5）：90-93.
[4] 邹桂年，邱前辉，叶宇东，等.鼻咽癌颈淋巴结转移相关甲基化基因的筛选[J].中山大学学报：医学科学版，2016， 37（4）：530-534.
[5] 任艳鑫，杨洁，孙瑞梅，等.vIL-10对鼻咽癌细胞株MCH-1类分子抗原加工提呈“操纵子”表达的影响[J]. 西安交通大学学报：医学版，2016，37（4）：525-530.
[6] 赵新星，张龙城，全超坤，等.EB病毒BRLF1基因及EB病毒Rta/IgG抗体在鼻咽癌中表达的临床意义[J].中国眼耳鼻喉科杂志，2016，16（4）：243-247.
[7] 中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范[M].北京：北京医科大学中国协和医科大学联合出版社，1991.
[8] 中国鼻咽癌TNM分期工作委员会.中国鼻咽癌分期2017版（2008鼻咽癌分期修订专家共识）[J].中华放射肿瘤学杂志，2017，26（10）：1119-1125.
[9] 杨志勇，黄晶.不同分期鼻咽癌治疗模式探讨[J].癌症进展，2017，15（1）：108-113.
[10] Qu Y，Wang D，Yang L，et al. Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma [J]. Molecular and Clin Oncol，2018， 34（5）：90-94.
[11] Li L，Li Y，Zhang J，et al. Optimization of cervical lymph node clinical target volume delineation in nasopharyngeal carcinoma：a single center experience and recommendation [J]. Oncotarget，2018，9（43）：45-47.
[12] 郑小雅，刘同欣，王方正，等.微信公众平台对鼻咽癌放疗患者治疗及护理依从性的影响[J].中国现代医生，2017， 55（2）：56-160.
[13] 杨颖，沈智超，刘芡芡，等.EB病毒编码基因BARF1对鼻咽癌细胞增殖和迁移影响[J].青岛大学医学院学报，2015，51（3）：261-263.
[14] 秦铀，胡彦，杨辰苏，等.鼻咽癌血清生物标志物研究新进展[J].中国癌症防治杂志，2017，9（4）：272-276.
[15] 高亚娜，陈涛.系统评估多个基因多态性位点与鼻咽癌易感性关联的Meta分析[J].中华临床医师杂志：电子版，2016，10（23）：3583-3587.
[16] 徐唐鹏，王琪，宋启斌.基因多态性与个体鼻咽癌易感性[J].武汉大学学报：医学版，2015，36（6）：1005-1010.
[17] 杨璐，王德辉.EB病毒引起的表观遗传学改变在鼻咽癌中的作用[J].中国眼耳鼻喉科杂志，2015，15（2）：138-140.
[18] 王伟娜，高翔翔，沈智超，等.鼻咽癌和健康人群中EB病毒BARF0基因序列分析[J].齐鲁医学杂志，2015，30（4）：383-385.
[19] Xu T，Su B，Huang P，et al. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load [J]. Proteomics Clin Appl，2017，11（5/6）.
[20] Zhang J，Shi H，Jiang T，et al. Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma [J]. BMC Cancer，2018，18（1）：45-47.
[21] Ouyang F，Guo B，Zhang B，et al. Exploration and validation of radiomics signature as an independent prognostic biomarker in stage Ⅲ-Ⅳb nasopharyngeal carcinoma [J]. Oncotarget，2017，8（43）：103-105.
[22] Gong D，Li Z，Ding R，et al. Extensive serum biomarker analysis in patients with nasopharyngeal carcinoma [J]. Cytokine，2018，34（7）：90-93. |
|
|
|
